Scroll Back to Top
Accessibility
Accessibility
<span>On-Demand Webinar: Systemic Mastocytosis - Insights Into A Rare Blood Disorder</span>
March 25, 2025

On-Demand Webinar: Systemic Mastocytosis - Insights Into A Rare Blood Disorder

Presented by guest speaker Dr. Alejandro Gru, MD, Professor of Dermatology and Director of Dermapathology at Columbia University’s Irving Medical Center, this webinar provides information about systemic mastocytosis, a rare blood disorder where abnormal mast cells (white blood cells) build up in different parts of the human body, resulting in a variety of symptoms. It is estimated that over 32,000 United States citizens could be living with this disease, and this webinar profiles what causes systemic mastocytosis, how this condition affects patients, how systemic mastocytosis can be detected and how are patients being treated for this disease.
Read more »
March 5, 2025

The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results, Practical Considerations for Personalized Cancer Care

For patients with advanced non-small cell lung cancer (NSCLC), tissue samples are typically small biopsies. These samples undergo standard of care evaluation for >10 biomarkers to identify targeted, personalized therapies. If only single-gene tests are ordered, it is unlikely all biomarkers will be successfully tested. Furthermore, the patient may not be able to get a second biopsy for comprehensive testing. Ordering single-gene tests before comprehensive profiling creates longer wait times for results, which can be problematic for selecting optimal treatment.
Read more »

Molecular Tumor Board: 47-year-old male with papillary thyroid cancer and BRAF V600E alteration

Molecular Tumor Board case for discussion: 47-year-old male with papillary thyroid cancer, harboring a BRAF V600E alteration. We discuss the diagnosis and risk stratification, including the role of fine needle aspiration and cytology to assess thyroid nodules. We also review management including surgery and the importance of lifelong thyroid replacement. Learn about the clinical journey of this rare cancer, with insights into genetic mutations, histologic features, and treatment strategies.

Read more »

Molecular Tumor Board: 38-year-old female with follicular thyroid cancer and NRAS Q61R alteration

In our latest molecular tumor board, our Medical Affairs team conducted an in-depth review of a case of follicular thyroid cancer with an NRAS mutation. Our team delved into the critical role of molecular profiling to identify the major oncogenic mechanisms driving thyroid carcinogenesis and emphasized the importance of thorough pathological and imaging evaluations for an accurate diagnosis of thyroid cancer.

Read more »

Labcorp Perspectives: Optimizing biomarker testing in advanced NSCLC: Insights on comprehensive genomic profiling (CGP)

In the latest episode of Labcorp Perspectives: Oncology, Dr. Rebecca Ann Previs and Dr. Kyle Strickland, directors of medical affairs at Labcorp Oncology, delve into the significant advantages of comprehensive genomic profiling (CGP) over single-gene testing in patients with advanced non-small cell lung cancer (NSCLC). This study, using OmniSeq® INSIGHT, showed that CGP enables that patients with NSCLC to be tested for all recommended biomarkers at once, providing the best chance of identifying effective treatment options.

Read more »

Molecular Tumor Board: 75-year-old male presents with a several month history of a painful tongue lesion and weight loss

In this Molecular Tumor Board we review cases of oral cavity squamous cell carcinoma and explore the clinical utility of lymphatic fluid collected from surgical drains as a novel source of ctDNA. This innovative approach from Droplet Biosciences offers potential for more precision monitoring and personalized treatment strategies. 

Presented by:

Wendy Winckler, PhD
Chief Science Officer
Droplet Biosciences

Jose Zevallos, MD, MPH
Scientific Co-founder
Droplet Biosciences

Read more »
Subscribe to Watch